Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

被引：37
|
作者：
Wang, Zhan [1 ]
Chen, Juan [2 ,3 ]
Zhong, Mei-Zuo [1 ]
Huang, Juan [4 ]
Hu, Yuan-Ping [4 ]
Feng, De-Yun [5 ]
Zhou, Zhi-Jiao [6 ]
Luo, Xiao [7 ]
Liu, Zhao-Qian [2 ,3 ]
Jiang, Wu-Zhong [1 ]
Zhou, Wei-Bing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
[4] Hunan Prov Clin Meditech Res Ctr Breast Canc, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Pathol, Changsha 410013, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Dept Pain, Changsha 410013, Hunan, Peoples R China
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2017年 / 79卷 / 03期
基金：
中国国家自然科学基金;
关键词：
ANLN; Breast cancer; Anthracycline; Prognosis; BINDING PROTEIN ANILLIN; DNA ADDUCTS; CYCLIN D1; ADJUVANT THERAPY; DOXORUBICIN; REPAIR; CYCLOPHOSPHAMIDE; EXPRESSION; RECOMBINATION; ACTIVATION;
D O I：
10.1007/s00280-017-3248-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
引用
收藏
页码：535 / 543
页数：9
相关论文
共 50 条
  • [1] Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
    Zhan Wang
    Juan Chen
    Mei-Zuo Zhong
    Juan Huang
    Yuan-Ping Hu
    De-Yun Feng
    Zhi-Jiao Zhou
    Xiao Luo
    Zhao-Qian Liu
    Wu-Zhong Jiang
    Wei-Bing Zhou
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 535 - 543
  • [2] Predictive factors for anthracycline-based chemotherapy for human breast cancer
    Miyoshi, Yasuo
    Kurosumi, Masafumi
    Kurebayashi, Junichi
    Matsuura, Nariaki
    Takahashi, Masato
    Tokunaga, Eriko
    Egawa, Chiyomi
    Masuda, Norikazu
    Kono, Seishi
    Morimoto, Koji
    Kim, Seung Jin
    Okishiro, Masatsugu
    Yanagisawa, Tetsu
    Ueda, Satsuki
    Taguchi, Tetsuya
    Tamaki, Yasuhiro
    Noguchi, Shinzaburo
    BREAST CANCER, 2010, 17 (02) : 103 - 109
  • [3] HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Yao, L.
    Liu, Y.
    Li, Z.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1326 - 1331
  • [4] Overexpression of Anillin (ANLN) is correlated with colorectal cancer progression and poor prognosis
    Wang, Guanghui
    Shen, Wei
    Cui, Long
    Chen, Wei
    Hu, Xuguang
    Fu, Jihong
    CANCER BIOMARKERS, 2016, 16 (03) : 459 - 465
  • [5] Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy
    Mendonca, M. A. O.
    Pereira, A. H. M.
    Silva, S. R.
    Mardegan, M. C.
    Murta, E. F. C.
    Tavares-Murta, B. M.
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (02) : 184 - 190
  • [6] Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
    Mina, Alain
    Rafei, Hind
    Khalil, Maya
    Hassoun, Yasmine
    Nasser, Zeina
    Tfayli, Arafat
    BMC CANCER, 2015, 15
  • [7] Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy
    Chan, Alexandre
    Chen, Christy
    Chiang, Joen
    Tan, Sze Huey
    Ng, Raymond
    SUPPORTIVE CARE IN CANCER, 2012, 20 (07) : 1525 - 1532
  • [8] Oxidative and antioxidative status after anthracycline-based chemotherapy in breast cancer patients
    Alacacioglu, A.
    Kebapcilar, L.
    Pamuk, B. Onder
    Sop, G.
    Kucukiravul, C.
    Bozkaya, G.
    Yuksel, A.
    Alacacioglu, I.
    Sari, I.
    JOURNAL OF BUON, 2013, 18 (03): : 614 - 618
  • [9] FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
    Xu, Y. L.
    Yao, R.
    Li, J.
    Zhou, Y. D.
    Mao, F.
    Pan, B.
    Sun, Q.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1205 - 1213
  • [10] Predictive factors for anthracycline-based chemotherapy for human breast cancer
    Yasuo Miyoshi
    Masafumi Kurosumi
    Junichi Kurebayashi
    Nariaki Matsuura
    Masato Takahashi
    Eriko Tokunaga
    Chiyomi Egawa
    Norikazu Masuda
    Seishi Kono
    Koji Morimoto
    Seung Jin Kim
    Masatsugu Okishiro
    Tetsu Yanagisawa
    Satsuki Ueda
    Tetsuya Taguchi
    Yasuhiro Tamaki
    Shinzaburo Noguchi
    Breast Cancer, 2010, 17 : 103 - 109
12345